Navigation Links
Horizon Therapeutics Announces Senior Management Appointments
Date:1/6/2009

SKOKIE, Ill., Jan. 6 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced the appointment of Amy Grahn to vice president, clinical operations and Iain Duncan to senior vice president of operations.

"Amy and Iain bring valuable operations experience that is vital as we prepare regulatory filings in the U.S. and Europe and move forward with the anticipated commercialization of our lead product candidate, HZT-501," said Timothy P. Walbert, president and chief executive officer. "During their respective careers, Amy and Iain have been instrumental in the growth of start-up as well as established biotech and pharmaceutical companies and their leadership will be an important part of Horizon's future growth."

Ms. Grahn has more than 20 years pharmaceutical industry experience spanning pre-clinical research to sales, with a primary focus on clinical operations. Ms. Grahn was most recently vice president of clinical operations at MedGenesis Therapeutix Inc. in British Columbia, Canada where she was responsible for strategic planning, development and implementation of clinical and pre-clinical development plans for therapeutic agents delivered via the MedGenesis convection-enhanced delivery (CED) platform.

During her career, Ms. Grahn has held various senior level positions at Neopharm, Inc., Takeda Pharmaceuticals North America, Inc., G.D. Searle & Company and Abbott Laboratories.

At Horizon, Ms. Grahn will lead all clinical operations activities. Ms. Grahn has a master's degree in biochemistry from Illinois Institute of Technology in Chicago and a bachelor's degree in chemistry and biology from Knox College in Galesburg, Ill.

Mr. Duncan has more than 20 years executive-level management experience in international, general and operations management. Mr. Duncan was a co-founder of Corus Pharma, I
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
2. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
3. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
4. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
5. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
8. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
9. BioHorizons Announces Agreement to Purchase Implant Logic Systems
10. Out beyond the horizon
11. Out beyond the horizon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... PRUSSIA, Pa. , July 28, 2015 ... Food and Drug Administration has accepted for review the ... recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of ... all primary endpoints. Hemophilia A ... or defective factor VIII; nearly all affected patients are ...
(Date:7/27/2015)...  Amgen (NASDAQ: AMGN ) today announced that ... Thursday, July 30, 2015, after the close of the ... a conference call with the investment community at 2 ... be Robert A. Bradway , chairman and chief ... team. Live audio of the conference call ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... announced a new video: 3 Ways to GHS Labels . This video ... the Globally Harmonized System (GHS) by effectively labeling chemical containers. , “With the ...
(Date:7/27/2015)... NEW YORK , July 27, 2015 /PRNewswire-USNewswire/ ... today announced the winners of its annual ... basic research by scientists who have been supported ... early career scientists to pursue innovative ideas in ... generate "proof" of concept for the early detection, ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Brady Releases “3 Roads to GHS Labels” Video 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... Indian company to purchase, distribute US-made bulk ... Specialty chemicals,maker Albemarle Corporation (NYSE: ... anti-inflammatory agent ibuprofen and other active pharmaceutical,ingredients ... pharmaceutical,company Dr. Reddy,s Laboratories Ltd. As per ...
... ST. JOSEPH, Mich., July 8 GeneGo, Inc., ... Keck Microarray Center,at Yale has become a certified ... access to GeneGo,s MetaCore, training and advanced,support., ... (Keck Lab),one of the largest biotechnology laboratories of ...
... market and business intelligence company, the enzyme market is significant ... 6.5 to 10%. Enzymes are sold in many different industry segments. ... , ... Paris (PRWEB) July 8, 2008 -- According ...
Cached Biology Technology:Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3Yale Keck Microarray Center Becomes a GeneGo Center of Excellence 2CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 2CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 3
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... April 14, 2013) Through a collaborative genome-wide study ... that are associated with heart rate. Since heart ... could provide a better understanding of genetic regulation of ... targets for new drugs to treat cardiovascular disease. ...
... 14, 2013)Drug-eluting stents can keep clogged leg arteries ... being presented at the Society of Interventional Radiology,s ... "Peripheral arterial disease (or PAD) is becoming increasingly ... obesity and diabetes epidemics," said Robert A. Lookstein, ...
... Injury: Latest News on Clinical Trials of Interventions to ... 17, 2013, from 4:30 to 6:30 p.m., at Kessler ... special Grand Rounds is presented by the Northern New ... Cord Injury Project of the W. M. Keck Center ...
Cached Biology News:Mount Sinai study identifies new gene variations associated with heart rate 2Drug-coated stents prevent leg amputation 2The State of Spinal Cord Injury Grand Rounds 2
... at the 9, 10, 12, and 13 positions. ... standard for the quantification of 13(S)-HODE by GC- ... of linoleic acid with plant and mammalian lipoxygenases. ... of tumor cells to the endothelium at concentrations ...
...
...
...
Biology Products: